The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
    • Content Hubs
Subscribe
Subscribe
The Medicine Maker / Issues / 2025 / Sept / Preparing for CPHI 2025 in Frankfurt
Industry News Sponsored

Preparing for CPHI 2025 in Frankfurt

Our interview with Tara Dougal offers a snapshot of what to expect at the event.

09/23/2025 0 min read

Sponsored By

Informa Markets

Share

Running from October 28 to 30 at Messe Frankfurt, Germany, CPHI Frankfurt is expected to draw more than 63,000 attendees. The event brings together professionals from across the drug development and manufacturing ecosystem, and will feature six content theaters, more than 2,000 exhibitors, and a packed program focusing on networking and innovation. New zones have also been introduced to spotlight topics such as digital health technologies, AI-powered drug development, and sustainable pharma manufacturing.

Learn more about the event in this interview with Tara Dougal, Event Director – Pharma at Informa Markets.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Recommended

Related Content

Caribou Halts Allogeneic CAR T Programs as Funding Pressures Mount
Cell & Gene Industry News
Caribou Halts Allogeneic CAR T Programs as Funding Pressures Mount

October 12, 2026

2 min read

“Caribou’s story has taken a heartbreaking turn,” says CEO Rachel Haurwitz, with the CRISPR-focused biotech set to discontinue vispa-cel and CB-011, and reduce its workforce

This Month’s Manufacturing Moves
Facilities & Equipment Business & Trends Industry News
This Month’s Manufacturing Moves

October 12, 2026

5 min read

Bayer plans a $2.2 billion Ohio campus, Genentech breaks ground in Oregon, and new investments support vaccine production, downstream processing, and manufacturing in orbit

Prula-cel Shows Early Promise in Lupus
Drug Delivery Cell & Gene Industry News
Prula-cel Shows Early Promise in Lupus

October 8, 2026

2 min read

Adicet Bio reports 12-month remission and renal response data for its allogeneic gamma delta CAR T therapy

Building a Pre-Disease Data Map
Industry News Future of Pharma Research News
Building a Pre-Disease Data Map

October 7, 2026

2 min read

Mayo Clinic and Thermo Fisher launch a large-scale multi-omics resource designed to reveal disease before symptoms appear

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: